Background Comparisons between ticagrelor and clopidogrel for the secondary prevention
of stroke in CYP2C19 loss-of-function carriers have not been extensively performed …

Embolic stroke of unknown source (ESUS) represents one in five ischemic strokes.
Ipsilateral non-stenotic carotid plaques are identified in 40% of all ESUS. In this narrative …

Introduction Clopidogrel is an antiplatelet agent recommended for secondary prevention of
ischemic stroke (IS) and transient ischemic attack (TIA). Conversion of clopidogrel to its …

Importance Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is effective in
preventing recurrent strokes after minor ischemic stroke or transient ischemic attack (TIA) …

BACKGROUND: It is unclear whether patients with different stroke/transient ischemic attack
etiologies benefit differently from gene-directed dual antiplatelet therapy. This study …

Importance Dual antiplatelet therapy (DAPT) with ticagrelor and aspirin has been found to
be effective for secondary prevention after minor ischemic stroke or transient ischemic attack …

Our aim was to investigate in a real‐life prospective patient cohort how CYP2C19 loss‐of‐
function (LOF) variants and CYP2C19 inhibitor omeprazole or esomeprazole influence the …

Background: It is unclear whether infarct location affects stroke recurrence after index
ischemic stroke. We aimed to compare the risk of stroke recurrence and the responses to …

Background Both inflammation and cerebral white matter injury are closely associated with
vascular cognitive impairment (VCI). The aim of this study was to analyze the correlation …

Objectives Evidence of the optimal antiplatelet therapy for elderly patients who had a stroke
is limited, especially those elder than 80 years. This study aimed to explore the efficacy and …